Marksans Pharma Ltd
₹216.17
(0.57%)
Sat, 30 May 2026, 02:18 pm
Health Technology
Pharmaceuticals: Major
24.5KMarksans Pharma Share Price Live Chart
1 Day
(0.57%)
No Result Found
Summary
Market Cap
11154.63
Net Profit
382.62
P/B
4.08
Sector P/E
34.30
P/E
26.47
EV/EBITDA
16.18
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.81
ROCE (Industry)
16.40
RONW (Industry)
14.39
ROE
16.89
ROCE
20.19
Debt/Equity
0.12
EPS (TTM)
9.22
Dividend Yield
0
Book Value
66.71
Interest Cover
44.22
Analysis
all
- Marksans Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Marksans Pharma is profitable, therefore cash runway is not a concern.
- Marksans Pharma is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (880.5%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 24.8x debt.
- Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Marksans Pharma's dividends as it is not paying a notable one for India.
- Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Marksans Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Marksans Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 43.87 | 43.87 | 43.87 | 43.87 | 43.87 |
| FII | 16.76 | 8.12 | 16.92 | 19.88 | 22.20 |
| DII | 6.57 | 5.91 | 5.28 | 5.50 | 4.56 |
| Public | 32.79 | 42.09 | 33.93 | 30.75 | 29.37 |
| Government | 0 | 0 | 0 | 0 | 0 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 250.46 | 215.38 | 200.01 | 180.30 | 164.93 | 145.22 | 110.14 |
| Fibonacci | 215.38 | 201.98 | 193.70 | 180.30 | 166.90 | 158.62 | 145.22 |
| Camarilla | 194.28 | 191.06 | 187.85 | 180.30 | 181.41 | 178.20 | 174.98 |
Pivots Level: Classic
R3
+70.16
250.46
R2
+35.08
215.38
R1
+19.70
200.01
S1
-15.38
164.93
S2
-35.08
145.22
S3
-70.16
110.14
Moving Average
Period
Value
10-EMA
228.61
20-EMA
215.54
30-EMA
207.26
50-EMA
197.69
100-EMA
189.78
200-EMA
192.23
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 26 May 2026 | board-meetings | Accounts, Quarterly Results, Dividend | |
| 05 Feb 2026 | board-meetings | Quarterly Results | |
| 13 Nov 2025 | board-meetings | Quarterly Results, Nine Months Results | |
| 11 Jul 2025 | agm | ||
| 01 Jul 2025 | dividend | Final Dividend - Rs. - 0.8 | 01 Aug 2025 |
| 19 May 2025 | dividend | ₹0.80 Dividend /Share | 01 Aug 2025 |
| 19 Aug 2024 | agm | ||
| 17 Aug 2024 | dividend | Final Dividend - Rs. - 0.6 | 17 Sept 2024 |
| 30 May 2024 | dividend | ₹0.60 Dividend /Share | 17 Sept 2024 |
| 02 Aug 2023 | agm |
Peer Comparison
Marksans Pharma Ltd
Sun Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd
Dr Reddys Laboratories Ltd
Divis Laboratories Ltd
Cipla Ltd
Marksans Pharma Ltd About
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two R&D centers, one located in Goa and the other in Navi Mumbai.
Industry
Pharmaceuticals - Indian - Formulations
Founded
1992
Headquarters
CEO
Mark Saldanha
Employees
Contact
Website
http://www.marksanspharma.com
companysecretary@marksanspharma.com ; info@marksan
Phone
91-22-40012000
Location
11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053
Marksans Pharma Ltd Company History
| Year | History |
|---|---|
| 2017 |
|
| 2021 |
|
| 2022 |
|
| 2023 |
|
| 2024 |
|
Deals
| Client Name | Deal Type | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|---|
| UNIFI CAPITAL PRIVATE LIMITED | bulk | Buy | 7241309 | 231.5 | 28 Jul 2025 |
| UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI | block | Buy | 3247600 | 249.95 | 11 Jun 2025 |
| SOCIETE GENERALE | block | Buy | 920184 | 249.95 | 11 Jun 2025 |
| UNIFI CAPITAL PRIVATE LIMITED | block | Buy | 594000 | 249.95 | 11 Jun 2025 |
| UNIFI BLEND FUND 2 | block | Buy | 3000000 | 249.95 | 11 Jun 2025 |
| UNIFI BCAD FUND | block | Buy | 560000 | 249.95 | 11 Jun 2025 |
| UTI MUTUAL FUND | block | Buy | 414093 | 249.95 | 11 Jun 2025 |
| CITIGROUP GLOBAL MARKETS SINGAPORE PTE LIMITED | block | Buy | 400081 | 249.95 | 11 Jun 2025 |
| BANDHAN MUTUAL FUND | block | Buy | 600000 | 249.95 | 11 Jun 2025 |
| SUBHKAM VENTURES I PRIVATE LIMITED | block | Buy | 537485 | 249.95 | 11 Jun 2025 |